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Pseudomonas aeruginosa Elastase Provides an Escape
from Phagocytosis by Degrading the Pulmonary
Surfactant Protein-A
Zhizhou Kuang1., Yonghua Hao1., Brent E. Walling1, Jayme L. Jeffries1, Dennis E. Ohman2, Gee W. Lau1*
1 Department of Pathobiology, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America, 2 Department of Microbiology and Immunology,
Virginia Commonwealth University School of Medicine, Richmond, Virginia, United States of America

Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that causes both acute pneumonitis in immunocompromised
patients and chronic lung infections in individuals with cystic fibrosis and other bronchiectasis. Over 75% of clinical isolates
of P. aeruginosa secrete elastase B (LasB), an elastolytic metalloproteinase that is encoded by the lasB gene. Previously, in
vitro studies have demonstrated that LasB degrades a number of components in both the innate and adaptive immune
systems. These include surfactant proteins, antibacterial peptides, cytokines, chemokines and immunoglobulins. However,
the contribution of LasB to lung infection by P. aeruginosa and to inactivation of pulmonary innate immunity in vivo needs
more clarification. In this study, we examined the mechanisms underlying enhanced clearance of the DlasB mutant in
mouse lungs. The DlasB mutant was attenuated in virulence when compared to the wild-type strain PAO1 during lung
infection in SP-A+/+ mice. However, the DlasB mutant was as virulent as PAO1 in the lungs of SP-A-/- mice. Detailed analysis
showed that the DlasB mutant was more susceptible to SP-A-mediated opsonization but not membrane permeabilization.
In vitro and in vivo phagocytosis experiments revealed that SP-A augmented the phagocytosis of DlasB mutant bacteria
more efficiently than the isogenic wild-type PAO1. The DlasB mutant was found to have a severely reduced ability to
degrade SP-A, consequently making it unable to evade opsonization by the collectin during phagocytosis. These results
suggest that P. aeruginosa LasB protects against SP-A-mediated opsonization by degrading the collectin.
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7,15,16]. Also, SP-A activates phagocytic cells and upregulates
the expression of host cell-surface receptors involved in microbial
recognition [8,17–21]. Most recently, we and others have reported
that SP-A also directly kills microbes in a macrophage-independent manner by increasing the permeability of microbial
membranes [22–27]. However, the mechanism by which SP-A
permeabilizes microbial membranes and its relative importance in
the lung defense is not clear. For example, it is not known whether
microbes that are membrane permeabilized by SP-A are
phagocytized more efficiently than the microbes with intact cell
membranes.
P. aeruginosa is a Gram-negative bacterial pathogen that causes
both acute pneumonitis in immunocompromised patients and
chronic lung infections in individuals with CF and non-CF
bronchiectasis, and chronic obstructive pulmonary disease
(COPD) [28–32]. Multiple virulence factors of P. aeruginosa
contribute to lung infection [33]. These virulence determinants
work in concert either offensively to inactivate components of host
immune response, or defensively to camouflage or evade host
response [33]. Cell surface associated virulence factors of P.
aeruginosa include pili, flagella, alginate, and lipopolysaccharides

Introduction
Pulmonary surfactant is a layer of lipoprotein complex with
critical surface tension lowering properties, which reduces the
work of breathing and helps to maintain airspace patency. Also, it
protects the lungs against inhaled air laden with microbes,
oxidants, pollutants and allergens [1–7]. About 10% of the
surfactant layer consists of proteins that have been identified as
surfactant protein-A (SP-A), SP-B, SP-C and SP-D. The lung
immune defense functions of surfactant are primarily mediated by
SP-A and SP-D, which are members of the collectin family of
proteins [2,6,8]. Severe depletion of SP-A and SP-D has been
associated with several respiratory diseases including bacterial
pneumonia, adult respiratory distress syndrome, and cystic fibrosis
(CF) [9–14]. SP-A-/- and SP-D-/- mice have been shown to be
more susceptible to lung infection by P. aeruginosa and other
pathogens [2,7,15].
In the past decades, studies have demonstrated that SP-A is an
important component of the pulmonary innate immune system.
SP-A opsonizes and enhances the phagocytosis of a myriad of
microbial pathogens in a calcium-dependent manner [2,3,6,
PLoS ONE | www.plosone.org
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(LPS) [33]. Type III and Type IV secretion effectors are injected
into the host cells to modulate host immune response [34–37].
Secreted components include exotoxin A, phospholipases, phenazines, rhamnolipids and exoproteases [33]. Among the exoproteases, elastase B (LasB), is a major elastolytic zinc metalloproteinase of 33 kDa encoded by the lasB gene of P. aeruginosa [38,39].
Also known as pseudolysin, LasB has received much attention and
been recognized as an important virulence factor. LasB is thought
to damage host tissues through hydrolysis of the components of
extracellular matrix and by breaching the endothelial and
epithelial barriers by attacking intercellular tight junctions
[40,41]. Under in vitro experimental conditions, LasB degrades
numerous components of innate and adaptive immune systems,
including SP-A and SP-D [42,43], cytokines and chemokines
TNF-a, IFN-c, IL-2 and IL-8 [40,44–47], and antibacterial
peptide [48]. Also, there are reports of elastase inactivating
secretory immunoglobulin A, immunoglobulin G and opsonin C3
[31,48–50]. Most recently, we have confirmed that P. aeruginosa
LasB is able to degrade lysozyme in vitro [22,51].
Despite numerous in vitro studies, direct evidence of LasBmediated proteolytic activities in the lungs, and to what extent they
contribute to the pathogenesis of P. aeruginosa requires more
investigation. In this study, we compared the virulence role of
LasB by using wild-type P. aeruginosa strain PAO1 versus an
isogenic DlasB mutant strain in an acute model of lung infection in
SP-A+/+ versus SP-A-/- mice.

Results
Figure 1. The DlasB mutant has severely attenuated exoprotease activity. (A) Western blot analysis of the LasB production in the
supernatant of PAO1, DlasB mutant and PDO240LasB as detected by
anti-LasB antibody. (B) Proteolytic activity of stationary phase culture
supernatant collected from PAO1, DlasB and PDO240lasB. Experiments
were performed independently three times in triplicates. The mean +
standard deviation from one representative experiment is shown.
*p,0.01 when comparing the exoprotease activity of DlasB against
PAO1 or PDO240lasB.
doi:10.1371/journal.pone.0027091.g001

The DlasB bacteria are severely attenuated in
exoprotease activities
We examined the amounts of LasB in the supernatants of
stationary phase P. aeruginosa cultures. As expected, the PDO240
mutant (Table 1) (from here in DlasB) bacteria did not secrete
LasB. In contrast, both the wild-type PAO1 and the genetically
complemented PDO240LasB bacteria produced the 33 kDa LasB
(Figure 1A). In addition, the DlasB bacteria had approximately 10fold less total exoprotease activity when compared to PAO1 and
PDO240LasB (Figure 1B).

By 36 hr, the number of bacteria for each strain in the SP-A+/+ mice
further decreased by approximately 0.5 log. However, the decrease
was not obvious in the Sp-A-/- mice (Figure 2B). These results
indicate that DlasB bacteria are more virulent in the lungs of SP-A-/mice than in the lungs of SP-A+/+ mice. Virulence attenuation in
DlasB bacteria was not due to reduced growth rate as wild-type
PAO1, DlasB and PDO240LasB bacteria had virtually identical
growth kinetics (Figure 2C).
Next, we examined various infected mouse lungs with
histopathological methods (Figure 3). Our analysis showed that
PAO1 and PDO240lasB caused more severe alveolitis with
pulmonary infiltrates (Figure 3A and 3E) whereas the DlasB
mutant only caused mild alveolitis in the lungs of SP-A+/+ mice
(Figure 3C). In contrast, PAO1, DlasB mutant and PDO240lasB
caused similar amounts of consolidation with more areas of
pneumonia in SP-A-/- lungs (Figure 3B, 3D, and 3F). These results
indicate that LasB plays an important protective role against antiP. aeruginosa activity mediated by SP-A.

The DlasB bacteria are cleared more efficiently following
lung infection in SP-A+/+ but not SP-A-/- mice
To determine the contribution of LasB to lung infection, we
compared the virulence of the wild-type P. aeruginosa PAO1, the
isogenic DlasB mutant, and the genetically-complemented strain
PDO240lasB in a mouse acute pneumonia model of single infection
studies. In the absence of bacterial infection, histopathological
features of SP-A-/- mouse lungs were indistinguishable when
compared to the lungs of SP-A+/+ mice (data not shown). Eighteen
hr after intranasal inoculation with PAO1 or PDO240lasB, SP-A+/+
mice showed signs of infection and respiratory distress but were not
moribund. In contrast, PAO1-infected SP-A-/- mice were moribund
and had to be euthanized (data not shown). The number of viable
wild-type PAO1 or PDO240lasB bacteria in SP-A-/- were 1.72 log
and 1.88 log higher than in SP-A+/+ mice, respectively (Figure 2A).
Eighteen hr after infection with the DlasB mutant bacteria, the lungs
of SP-A+/+ mice showed little sign of disease. In contrast, SP-A-/infected with DlasB mutant bacteria developed significant respiratory distress or were moribund, and had to be euthanized (data not
shown). The viable counts of DlasB mutant were 1.5 log lower than
PAO1 in SP-A+/+ mice. However, the number of DlasB bacteria was
3.1 log higher in SP-A-/- mice than in SP-A+/+ mice, and was
statistically indistinguishable when compared to the number of
PAO1 and PDO240lasB bacteria in the SP-A-/- mice (Figure 2A).
PLoS ONE | www.plosone.org

The DlasB bacteria are deficient in their ability to degrade
SP-A
Previously, it has been shown that P. aeruginosa elastase degrades
human SP-A (hSP-A) [22,43,52]. Here, we examined the ability of
DlasB mutant on its ability to degrade hSP-A. The hSP-A (25 mg)
was incubated with 16108 wild-type PAO1, DlasB, or genetically
2
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Table 1. P. aeruginosa strains used in this study.

Bacterial Strains

Relevant characteristics

Reference

P. aeruginosa
PAO1

Wild-type

M. Vasil, 58

PAO1-gfp

PAO1 strain harboring the green fluorescent protein expression broad host range plasmid pUCP19-gfp

This study

PDO240 (DlasB)

Elastase-deficient mutant derived from PAO1

[57]

DlasB -gfp

DlasB mutant harboring GFP plasmid pUCP19-gfp

This study

PDO240lasB

DlasB mutant harboring a wild-type lasB gene on plasmid pKSM3

This study

F-f80 DlacZDM15 endA1 recA1 hsdR17 (r-km+k) supe44 thi-1 l-gyr A96 relA1 D(lacZYA-argF) U169

[66]

E. coli
DH5a
Plasmids
pUCP19-gfp

Broad host range vector. Polylinker lacZ, laciq selection, bla, gfp

[26]

pKSM3

pLAFR3 with lasB gene on a 2.6 kb EcoRI-Pstl fragment

[65]

doi:10.1371/journal.pone.0027091.t001

complemented PDO240lasB bacteria (Table 1) for the indicated
time intervals. After 6 hr of incubation, the degradation of hSP-A
by PAO1 and PDO240lasB bacteria was evident (Figure 4A). By
18 hr post incubation, hSP-A was almost completely degraded by
PAO1 and PDO240lasB. In contrast, there was only minimal
degradation of hSP-A by the DlasB bacteria, with majority of the
collectin remaining intact even after 18 hr of exposure (Figure 4A).
Densitometry analysis indicates that PAO1 degraded approximately 40% hSP-A after 6 hr incubation. By 12 and 18 hr,
majority of the hSP-A had been degraded (Figure 4B). Increasing
amount of hSP-A degradation was correlated with higher amount
of LasB secretion by PAO1 and PDO240lasB as the time of
incubation was lengthened (Figure 4C). The degradation of SP-A
was not influenced by the presence or absence of Zn2+, suggesting
that LB provided sufficient Zn2+ for the proteolytic activities of
LasB (Figure S1). These results suggest that DlasB bacteria are
strongly attenuated in their ability to degrade hSP-A, and that
LasB is a major exoprotease of P. aeruginosa that is responsible for
the removal of hSP-A.

LasB-secreting PAO1 or PDO240lasB would inactivate the ability
of mSP-A within lung BAL fluids to permeabilize microbial
membranes. To further assess the function of LasB against mSPA in vivo, we compared the ability of BAL fluids from 18 hr postinfection (from Figure 5C) to permeabilize the membrane of E. coli
DH5a. Purified hSP-A was used as a positive control. Pure hSP-A
has the highest levels of membrane permeabilization activity, which
was 2.3 and 2.5 fold higher than BAL fluids from PAO1 and
PDO240lasB infected SP-A+/+ mice after 90 min of incubation
(Figure 5E). In contrast, even though the extent of membrane
permeabilization on DH5a mediated by pure hSP-A was
consistently higher than BAL fluids from DlasB-infected animals,
the difference was not statistically significant (Figure 5E). Importantly, BAL fluids from PAO1 or PDO240lasB -infected SP-A+/+
mouse lungs, where mSP-A had been degraded by LasB, showed
lower ability to permeabilize DH5a (Figure 5E). On the contrary,
BAL fluids from DlasB-infected mice permeabilized DH5a bacteria
at 1.9 and 2.1 fold higher than BAL from PAO1 and PDO240lasB,
respectively, after 90 min of exposure (Figure 5E). Taken together,
these results suggest that during infection of mouse lungs, P.
aeruginosa protects itself against the antimicrobial activities of mSP-A
by degrading the collectin through the secretion of LasB.

The DlasB bacteria are impaired in the degradation of SPA during infection of SP-A+/+ mouse lungs
Although in vitro studies have shown that P. aeruginosa secretes
elastase to degrade SP-A [22,43,52], the biological importance of
SP-A removal by LasB and the resulting resistance to clearance
during infection of SP-A+/+ lungs have not been investigated. We
compared the in vivo degradation of mouse SP-A (mSP-A) by wildtype PAO1, the elastase-deficient mutant DlasB, and the complemented strain PDO240lasB in SP-A+/+ mice. The amounts of mSPA in the BAL fluids from mice infected with all three bacterial
strains were similar at 6 hr (Figure 5A) and 12 hr post-infection
(Figure 5B). However, by 18 hr post-infection, PAO1 or PDO240lasB had significantly lower amounts of mSP-A. In contrast,
significant amounts of intact mSP-A dimers and monomers were
detected in the BAL of mice infected with DlasB bacteria (Figure 5C).
Western blot data were confirmed by densitometry analyses, which
showed that both PAO1 and PDO240lasB degrade significantly
more mSP-A than DlasB mutant (Figure 5D). These results suggest
that LasB plays important role in removal of mSP-A in vivo.
A previous study has suggested that mSP-A is a principal factor
that permeabilizes microbial membranes in the alveolar lining fluid
of mouse lungs [53]. Thus, proteolytic degradation of mSP-A by
PLoS ONE | www.plosone.org

The DlasB bacteria are not susceptible to SP-A-mediated
membrane permeabilization
Previous studies have demonstrated that SP-A protects lungs
against microbial infection by opsonization [2,3,7,15]. More
recently, we and others have shown that SP-A is capable of
directly killing microbes in a macrophage-independent manner, by
permeabilizing microbial membranes [22–27]. We examined
which defense mechanism(s) led to enhanced clearance of DlasB
bacteria in the lungs of SP-A+/+ mice. Previously, we have
reported that the wild-type P. aeruginosa strain PAO1 is resistant to
hSP-A-mediated membrane permeabilization [22,26,27]. First, we
compared the susceptibility of the DlasB mutant to hSP-Amediated membrane permeabilization against its parental wildtype PAO1 and the complemented strain PDO240lasB. E. coli
DH5acells incubated with hSP-A were used as positive control. As
expected, hSP-A permeabilized the membrane of DH5a cells
(Figure 6). In contrast, PAO1, DlasB, and PDO240lasB bacteria
demonstrated similar levels of resistance to hSP-A-mediated
membrane permeabilization (Figure 6). These results suggest that
3
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mSP-A-mediated membrane permeabilization is not responsible
for the enhanced clearance of DlasB bacteria in mouse lungs.

The DlasB bacteria are unable to degrade SP-A and are
more susceptible to SP-A-mediated opsonization in vitro
Previously, P. aeruginosa has been shown to be susceptible to SPA-mediated opsonization [54,55]. Because the DlasB mutant
bacteria were not sensitive to hSP-A-mediated membrane
permeabilization, we examined whether they were more susceptible to hSP-A-mediated opsonization. Bacterial phagocytosis
assays were performed using the murine macrophages RAW
264.7. The number of P. aeruginosa cells internalized by
macrophages RAW 264.7 was enumerated by gentamicin
exclusion assays [56]. The presence of hSP-A significantly
increased the phagocytosis of both the wild-type PAO1 and DlasB
mutant by macrophages in a concentration dependent manner
(Figure 7A). When exposed to 10, 20, or 50 mg/ml of hSP-A, the
number of DlasB bacteria internalized by macrophages was 2.3,
3.6 and 3.8 fold higher respectively compared to DlasB without
hSP-A treatment in 60 min. However, the increase in the
phagocytosis of DlasB bacteria was statistically indistinguishable
from PAO1. These results suggest that the ability of PAO1
bacteria to secrete LasB does not significantly interfere with the
ability of hSP-A to opsonize the bacteria within the short duration
(1 hr) under our in vitro experimental conditions. This observation
is not surprising because a large amount of intact hSP-A still
remained after 6 hr of exposure to PAO1, partly due to high
amounts of hSP-A (25 mg) used in the experiments (Figure 4).
Next, we examined the impact of prolonged exposure of hSP-A to
PAO1 or DlasB on the ability of the collectin to opsonize the bacteria.
hSP-A (20 mg/ml) was preincubated with PAO1 or DlasB for 1, 6, 12
or 18 hr before the mixture was added to the macrophages for
phagocytosis assays. After 60 min of phagocytosis, internalized
bacteria were enumerated by gentamicin exclusion assay. The
number of internalized PAO1 decreased gradually in a timedependent manner (Figure 7B), in an inverse relationship to the
degradation of hSP-A (Figure 4). By 12 and 18-hr, the number of
PAO1 bacteria internalized by macrophages was 1.7-fold and 2.2fold lower than the DlasB bacteria, respectively (Figure 7B). As
expected, because of its greatly reduced ability to degrade hSP-A, the
phagocytosis rate of DlasB bacteria remained nearly constant
throughout the entire experiment. Even though there was a slight
decrease in the number of DlasB bacteria internalized by macrophages exposed to the bacteria/hSP-A mixture from the 12th and
18th-hr, the decrease was not statistically significant (Figure 7B).
These results are consistent with the observation that DlasB bacteria
lack the ability to degrade hSP-A, and are subsequently opsonized by
the collectin and phagocytized by macrophages.

Figure 2. The DlasB mutant is attenuated for virulence in SP-A+/+
mice. (A) Respiratory tract infections with wild-type PAO1, DlasB
mutant or genetically-complemented PDO240lasB bacteria were
performed by intranasal inoculation of anesthetized SP-A+/+ or SP-A-/mice. Mouse lungs were harvested 18 hr after infection for CFU
enumeration. Data are the mean CFU 6 SE (n = 5 per group). * p,0.05
when comparing lungs of SP-A+/+ mice infected with PAO1 and
PDO240lasB versus DlasB; ** p,0.05 when compared between SP-A+/+
and SP-A-/- mice infected with PAO1, DlasB or PDO240lasB bacteria. (B)
Mouse lungs were harvested 36 hr after infection for CFU enumeration.
Data are the mean CFU 6 SE (n = 5 per group). * p,0.05 when
comparing lungs of SP-A+/+ mice infected with PAO1 and PDO240lasB
versus DlasB; ** p,0.05 when compared between SP-A+/+ and SP-A-/mice infected with PAO1, DlasB or PDO240lasB bacteria. (C) Attenuation
of DlasB bacteria in mouse lungs was not due to a slower growth rate.
Bacterial growth was assessed by absorbance at OD600. The data from
one of the three independent experiments are shown.
doi:10.1371/journal.pone.0027091.g002

PLoS ONE | www.plosone.org

The DlasB mutant bacteria are more susceptible to mSPA mediated opsonization in vivo
The in vitro phagocytosis results presented in Fig. 6 suggest that
proteolytic degradation of SP-A is required to negate enhanced
clearance of P. aeruginosa by macrophages. We examined this
possibility by performing in vivo phagocytosis assays. After infection
with the wild-type PAO1 or DlasB bacteria, mouse lungs were
lavaged at 6, 12 and 18 hours post infection. Bacteria that were
internalized by lung leukocytes within the BAL fluids were
enumerated by gentamicin exclusion assays. As shown in
Figure 8A, the number of internalized DlasB bacteria was not
different than internalized PAO1 bacteria at 6 and 12 hr postinfection. However, by 18 hr post infection, the number of
internalized DlasB bacteria was 2.6 fold higher than PAO1. The
4
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Figure 3. Histopathology of P. aeruginosa infected lungs. Representative H&E-stained lung sections from SP-A+/+ and SP-A-/- mice (n = 5) 18-hr
post intranasal instillation of PAO1 (A-B), DlasB (C-D) and PDO240lasB (E-F) bacteria.
doi:10.1371/journal.pone.0027091.g003

BAL fluids at 18 hr post-infection (Figure 9B). The DlasB-GFP
bacteria were frequently found in aggregates, suggesting of
opsonization by mSP-A (Figure 9B, arrows). In contrast, no
aggregates of PAO1-GFP bacteria were apparent in infected
mouse lungs. Taken together, these results suggest that failure by
the DlasB bacteria to degrade SP-A allows the collectin to
effectively aggregate, opsonize and facilitate the phagocytosis and
preferential clearance of the LasB-deficient bacteria.

latter time point correlates with the time interval when a significant
amount of mSP-A is degraded by PAO1 bacteria (Figure 5C) but
not by the DlasB bacteria. The increase in the phagocytosis of DlasB
bacteria was not due to disproportionately higher levels of
professional phagocytes because flow cytometry analyses showed
that both PAO1 and DlasB-infected mouse lungs had similar
numbers of neutrophils and macrophages (Figure 8B). Leukocytes
analysis was supported by ELISA assays, which indicated that the
levels of the neutrophil and macrophage chemotactic chemokines
CCL5 and MCP1 were not statistically different between mouse
lungs infected with PAO1, DlasB or PDO240lasB (Figure 8C).
These results suggest that the DlasB bacteria were unable to protect
themselves from mSP-A-mediated opsonization in vivo due to their
inability to remove the collectin through proteolytic degradation.

DlasB bacteria are attenuated in degradation of
pulmonary innate immunity protein lysozyme
Our phagocytosis assays shown above have demonstrated that
SP-A enhances the phagocytosis of P. aeruginosa by ,2-3 fold.
However, the final difference in bacterial load of SP-A+/+ versus
SP-A-/- is , 100 fold (Figure 2A), suggests that LasB may be
required to degrade other components of pulmonary antimicrobial
proteins. We examined whether the DlasB bacteria are attenuated
in degradation of lysozyme, which has been previously shown to
be important against P. aeruginosa [57]. In addition, we have
previously shown that SP-A and lysozyme act synergistically to
permeabilize the membranes of wild-type P. aeruginosa strain PAO1
[22]. Given this unanticipated discrepancy, we examined in vitro
and in BAL fluids of infected mouse lungs for evidence of reduced
degradation of lysozyme. As shown in Figure 10, LasB was able to
degrade lysozyme both in vitro and in vivo experimental conditions.
To confirm lysozyme degradation, we incubated 5 mg/ml

Aggregation of DlasB bacteria in the presence of SP-A
SP-A aggregates microbes, which are phagocytized at higher
efficiency by professional phagocytes [2,3,7,16]. We used fluorescent microscopy to examine whether there was a difference in the
efficiency of SP-A-mediated aggregation of GFP-expressing PAO1
versus DlasB bacteria. As shown in Figure 9A, after 120 min of
aggregation by hSP-A, the number of DlasB-GFP aggregates was
slightly higher than PAO1-GFP. However, the increase was not
statistically significant. This is not surprising considering that
excess amounts of intact hSP-A still present in the mixture
(Figure 4A). Also, we examined the bacterial aggregates in the
PLoS ONE | www.plosone.org
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Figure 4. SP-A-degrading ability is reduced inDlasB mutant bacteria in vitro. (A) hSP-A (25 mg) was incubated with 16108 PAO1, DlasB or
PDO240LasB bacteria for the indicated time intervals. hSP-A degradation was assessed by western blot analyses using 10 ml of SP-A/bacterial
suspension. Image from one of the three independent experiments is shown. (B) Densitometry quantification of hSP-A degradation in A. (C)
Production of LasB in the mixture was assessed by western blot analyses using 10 ml of supernatant from the hSP-A/bacterial suspension.
Immunoblots were probed with anti-SP-A (A) or anti-LasB (C) antibody, respectively.
doi:10.1371/journal.pone.0027091.g004

lysozyme with 16108 PAO1, DlasB, and PDO240lasB bacteria.
After 18 hr incubation, lysozyme exposed to DlasB mutant
remained intact (Figure 10A). In contrast, PAO1 or PDO240lasB
bacteria were able to degrade lysozyme (Figure 10A). Similarly,
BAL samples from mice infected with PAO1 or PDO240lasB had
reduced amounts of lysozyme (Figure 10B). In contrast, BAL
samples from mice infected with DlasB mutant still contained
intact lysozyme. Densitometry quantifications indicated that by
18 hr, PAO1 and PDO240lasB had degraded 50-60% more
lysozyme than the DlasB mutant in vitro (Figure 10C) and in vivo
(Figure 10D). Thus, infection by P. aeruginosa likely induced the
expression of lysozyme, which was subsequently degraded by LasB
and other exoproteases produced by PAO1 or PDO240lasB. In
contrast, due to inability of the DlasB mutant to elaborate
adequate exoprotease activity, lysozyme remained intact.

intercellular junctions of lung epithelia, LasB also is capable of
degrading components of the innate and acquired immune system,
including cytokines and chemokines, antimicrobial peptides,
immunoglobulins, serum complement factors, and surfactant
protein [31,40,43–50,58,59]. However, most of these studies were
performed in vitro with a combination of purified elastase and
purified host components, or purified host component exposed to
P. aeruginosa. Thus, direct proof of LasB-mediated proteolysis in
lung infection is lacking. In this study, we provide evidence that P.
aeruginosa elastase reduces the phagocytosis of the bacteria in
mouse lungs by degrading SP-A, an important innate immune
system component that opsonizes and membrane permeabilizes
microbes. By comparing lung infections between SP-A+/+ and SPA-/- mice using a combination of wild type P. aeruginosa strain
PAO1 and isogenic mutant strain DlasB, we demonstrate that: (i)
the DlasB mutant is attenuated in the lungs of SP-A+/+ mice but is
fully virulent in the lungs SP-A-/- mice; (ii) inability to secrete LasB
impairs the ability of P. aeruginosa to degrade SP-A both in vitro and
in mouse lungs; (iii) LasB deficiency does not result in increased

Discussion
P. aeruginosa LasB is an important virulence factor during host
infections. In addition to damaging tissues and disrupting
PLoS ONE | www.plosone.org
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Figure 5. Elastase deficient DlasB mutant is attenuated in the degradation of SP-A during lung infection. (A-C) The amounts of intact
mSP-A were not visibly changed at 6-hr (A) or 12- hr (B) post-infection. By 18 hr post-infection (C), intact mSP-A was reduced in the BAL fluid from
PAO1- or PDO240lasB-infected SP-A+/+ mice (n = 6), suggesting that mSP-A was degraded in mouse lungs. In contrast, more abundant mSP-A was
clearly visible in the BAL fluids from DlasB (n = 8). C = Purified human SP-A. M1 – M8 = BAL of mice infected with P. aeruginosa. Western blot
analyses were performed using a polyclonal antibody against SP-A. (D) Densitometry analysis of mSP-A degradation by PAO1, DlasB and PDO240lasB
in mouse lungs. The amounts of remaining mSP-A in DlasB were set to the value of 100%. *p,0.05 when compared the amount of mSP-A in BAL
fluids from lungs infected with PAO1 or PDO240lasB against BAL fluids from DlasB-infected mice. (E) Mouse BAL from DlasB-infected animals contains
intact mSP-A that permeabilizes bacterial membranes. Pooled BAL fluids (from C) (50 mg/ml total proteins) were used for membrane permeabilization
assays. hSP-A (50 mg/ml) was used as positive control. BAL fluids from PAO1 and PDO240lasB infected mice failed to permeabilize E. coli membranes.
hSP-A and BAL samples from DlasB-infected mice were able to permeabilize bacterial membranes of E. coli DH5a at higher levels. Experiments were
performed independently three times in triplicates. The mean + standard deviation from one representative experiment is shown. **p,0.05 from
60 min onward when comparing the membrane permeabilization of E. coli by pure SP-A or BAL samples from DlasB-infected mice against BAL
samples from PAO1 or PDO240lasB-infected mice.
doi:10.1371/journal.pone.0027091.g005

susceptibility of P. aeruginosa to membrane permeabilization by SPA; (iv) failure to degrade mSP-A results in increased opsonization
and enhanced clearance of the DlasB mutant from the lungs of SPA+/+ mice; (v) substantial amounts of SP-A degradation by LasB
needs to occur before the phagocytosis of P. aeruginosa by
professional phagocytes is significantly reduced. Collectively, these
results suggest that LasB affords a protective role to P. aeruginosa by
negating the ability of SP-A to serve as an opsonin that helps to
augment phagocytosis.
In vitro degradation of hSP-A by exoproteases of P. aeruginosa was
previously reported [43,52]. These authors observed the degradation of hSP-A when the collectin was co-cultured with P.
aeruginosa, and with BAL fluids from the lungs of CF patients
PLoS ONE | www.plosone.org

chronically colonized by the bacterial pathogen. After purification
and mass spectroscopy analysis, the proteolytic enzyme was
identified as P. aeruginosa elastase. By comparing the infection of
SP-A+/+ versus SP-A-/- mouse lungs using both wild-type PAO1
and the DlasB mutant, we reveal that LasB plays an important role
in negating the innate immunity role of mSP-A through
proteolytic degradation of the collectin.
Apart from serving as an opsonin, SP-A also has the ability to
permeabilize microbial membranes, similar to antimicrobial
peptides [22,23,26,27,58,60]. It has been suggested that SP-A
may be one of the major lung innate immunity proteins that
permeabilize bacterial membranes [53]. However, we have
reported that wild-type P. aeruginosa is resistant to SP-A-mediated
7

November 2011 | Volume 6 | Issue 11 | e27091

Pseudomonas Elastase Inhibits Opsonization by SP-A

Figure 6. DlasB mutant bacteria are resistant to SP-A-mediated
membrane permeabilization. Membrane permeabilization assays
were performed with 16108 of E. coli DH5a or P. aeruginosa exposed to
hSP-A (50 mg/ml) for 120 min. Three independent experiments were
performed in triplicates. The mean + standard deviation from one
representative experiment is shown. The membrane permeabilization
activity of hSP-A against PAO1, DlasB and PDO240lasB was not
statistically different among all three P. aeruginosa strains. *p,0.05
from 35 min onward when comparing the membrane permeabilization
of DH5a against PAO1, DlasB and PDO240lasB.
doi:10.1371/journal.pone.0027091.g006

membrane permeabilization [26,27]. P. aeruginosa confers resistance to SP-A-mediated membrane permeabilization by elaborating LPS, flagella, phosphoenolpyruvate phosphotransferase and
salicylate biosynthesis, and exoproteases [22,26,27]. Especially
interesting is that the loss of flagella seems to reduce the ability of
P. aeruginosa to synthesize adequate LPS, resulting in increased
susceptibility to SP-A. Furthermore, flagella-deficiency also causes
P. aeruginosa to produce less exoproteases [22]. As we have shown
here, the loss of LasB, a major exoprotease in P. aeruginosa, renders
the pathogen susceptible to increased clearance from lungs
through opsonization, not membrane permeabilization. However,
we have previously shown that the flagella-deficient mutants of P.
aeruginosa do not exhibit increased susceptibility to SP-A-mediated
opsonization. This discrepancy could be explained because the in
vitro and in vivo phagocytosis studies of the flagella mutants were
performed for only 60 - 120 minutes [26], and the data is similar to
what we have observed for the DlasB mutant, where phagocytosis
was carried out for 60 min (Fig. 5). However, as we have
demonstrated, wild-type P. aeruginosa PAO1 induces a timedependent degradation of SP-A with a corresponding reduction
in SP-A-mediated opsonization at 6-hr or longer post-incubation
in vitro, or 18 hr in vivo. In contrast, the DlasB mutant bacteria are
unable to degrade adequate amounts of SP-A, and are increasingly
cleared by hSP-A-augmented phagocytosis by RAW 246.7
macrophages through the 18 hr incubation. We are currently
performing experiments to clarify the relationship between
exoprotease deficiency of flagella mutants and susceptibility to
SP-A-mediated opsonization.
Our comparative in vivo phagocytosis assays indicate that the
differences between the number of PAO1 and DlasB bacteria
internalized by pulmonary leukocytes are only apparent 18 hr
PLoS ONE | www.plosone.org

Figure 7. The DlasB mutant is unable to degrade and impede
SP-A-mediated opsonization in vitro. (A) hSP-A opsonized and
increased the phagocytosis of both wild-type PAO1 and DlasB bacteria
in a concentration dependent manner. ,16107 PAO1 or DlasB bacteria
were treated with PBS alone or with increasing concentrations of hSP-A
for 1 hr in the presence of 16106 cultured RAW 264.7 macrophages.
The number of phagocytized bacteria was determined by gentamicin
exclusion assay. The fold increase in phagocytosis was calculated based
on the number of engulfed bacteria in macrophages treated with hSP-A
versus PBS alone. Three independent experiments were performed in
triplicates. The mean + standard deviation from one representative
experiment is shown. *, **p,0.01 when comparing the internalized
PAO1 or DlasB mutant pretreated with various concentrations of hSP-A
versus PBS alone. (B) The DlasB mutant bacteria are more susceptible to
hSP-A-mediated opsonization. hSP-A (20 mg/ml) was incubated with
16107 PAO1 or DlasB bacteria for 1, 6, 12, or 18 hr. At indicated time
intervals, the bacteria-hSP-A mixture was added to 16106 cultured RAW
264.7 macrophages, and incubated for another 1 hr. The number of
engulfed bacteria was examined as in (A), and normalized against PAO1
or DlasB bacteria phagocytized in the absence of hSP-A. Three
independent experiments were performed in triplicates. The mean +
standard deviation from one representative experiment is shown.
*p,0.01 when comparing the number of phagocitized DlasB bacteria
against internalized PAO1 bacteria.
doi:10.1371/journal.pone.0027091.g007

post-infection, but not at earlier time points. This observation is
reflective of the amounts of intact mSP-A remaining in the infected
lungs, which are not substantially degraded until 18 hr post8
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infection. These results suggest that the kinetics of mSP-A
degradation are slower during lung infection. This is not surprising
considering the complexity of the pulmonary immune response
during an acute pneumonia infection. For example, it is known
that neutrophil elastase also degrades SP-A [60,61]. Thus, at 18 hr
post-P. aeruginosa infection when the neutrophil influx is prominent
(Fig. 7B), it is possible that a combination of LasB, other minor P.
aeruginosa exoproteases and neutrophil elastase all combine to
afford a quantifiable difference in mSP-A degradation to result in
an alteration in the phagocytosis of PAO1 and DlasB. However,
the contribution of neutrophil elastase seems less likely because
infections by both PAO1 and DlasB result in similar leukocytic
infiltration. In addition, the loss of LasB function should trigger P.
aeruginosa to overproduce other exoproteases to compensate for the
loss of the former, or at least maintain the secretion of these
exoproteases at the wild-type levels.
It is known that P. aeruginosa has a propensity to reduce the
expression of many virulence factors such as elastase, lipase,
exotoxin A, etc., during chronic infection of CF airways [33]. In
contrast, many of these clinical CF isolates overproduced alginate, a
major polysaccharide capsule, resulting in a mucoid phenotype.
Mucoid P. aeruginosa are more resistant to phagocytosis. Previously,
it was shown that LasB plays a role in the biosynthesis of alginate
[62]. Overexpression of LasB in both mucoid and non-mucoid P.
aeruginosa cells, stimulates alginate synthesis [62]. Mechanistically,
this is achieved by a genetic rearrangement that triggers mucoidy in
P. aeruginosa, which also allows retention of elastase in the periplasm
in an active oligomeric form. The LasB cleaves the 16 kDa form of
nucleoside diphosphate kinase (Ndk) to a truncated 12 kDa form.
Processed NdK is important for the generation of GTP required for
alginate synthesis [62]. Thus, the loss of LasB may negatively affect
alginate production, resulting in increased susceptibility to SP-Amediated opsonization. Even though we cannot rule out this
possibility, we predict that the effect of alginate is minimal since it is
only present in limited amounts in non-mucoid P. aeruginosa.
Collectins, including SP-A, frequently bind and aggregate
microbes. Aggregated microorganisms are phagocytized at higher
efficiency [2,3,7,16]. van Rozendaal et al reported that SP-D
inhibits protein synthesis and hyphal outgrowth in Candida albicans
[63]. These authors speculated that inhibition of protein synthesis
was an indirect consequence of fungal aggregation restricting
access of the organisms to essential nutrients. Undoubtedly,
aggregation of DlasB mutant bacteria but not wild-type PAO1 at
late stages of infection promotes more efficient clearance of the
former. We are currently determining whether aggregation of
DlasB bacteria is limiting access to nutrients.
One unresolved issue regarding our study is the relative
contribution of SP-A versus other pulmonary innate immunity
proteins in controlling P. aeruginosa infection. As we have discussed,
exposure to SP-A increases the phagocytosis of P. aeruginosa by 2-3
fold, and that at late stages of acute pneumonia infection, the DlasB
mutant bacteria are phagocytized better than the wild-type PAO1
because of the latter’s ability to degrade mSP-A. However, it was
likely that a 2-3 fold increase in phagocytosis would not have
accounted for ,100 fold increase in the clearance of DlasB mutant
bacteria. ELISA assays indicated that the levels of neutrophil and
macrophage chemotactic chemokines CCL5 and MCP1 in the
mouse lungs infected by PAO1 versus DlasB were not significant
different, suggesting that these chemokines were not susceptible to
degradation by LasB. However, additional experiments suggest that
LasB is also a major exoprotease that degrades lysozyme, which is
known to have antimicrobial activities [57]. Thus, we cannot rule
out that a synergistic or additive role of various pulmonary innate
immunity proteins, which are susceptible to LasB degradation, may

Figure 8. The DlasB mutant bacteria are more susceptible to SPA-mediated opsonization in vivo. (A) SP-A+/+ mice were intranasally
infected with 16107 of wild-type P. aeruginosa PAO1 or DlasB bacteria.
At each time interval, infected mice (n = 5) were lavaged for
macrophages and infiltrating leukocytes. Cells were centrifuged,
washed and the engulfed bacteria were enumerated by gentamicin
exclusion assay. Changes in bacterial phagocytosis were calculated
based on the number of intracellular PAO1. The mean + standard
deviation is shown. *p,0.01 when comparing the number of
internalized DlasB bacteria against PAO1 bacteria. (B) Leukocyte profiles
in mouse lungs infected with PAO1 or DlasB bacteria. Macrophages and
neutrophils within BAL fluids were determined using antibody specific
against each cell type by using flow cytometry. (C) Profiles of
macrophage and neutrophil chemotactic chemokines CCL5 and MCP1
in mouse lungs infected with PAO1, DlasB or PDO240lasB bacteria.
doi:10.1371/journal.pone.0027091.g008
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Figure 9. The DlasB mutant bacteria are more susceptible to SP-A-mediated aggregation in vivo. (A) In vitro aggregation of GFPexpressing wild-type P. aeruginosa PAO1 or DlasB bacteria co-incubated with hSP-A and observed under fluorescent microscopy. (B) In vivo
aggregation of GFP-expressing wild-type P. aeruginosa PAO1 or DlasB (arrows) bacteria lavaged from mouse lungs 18-hr post-infection (n = 5)
observed under FLUOVIEW FV300 confocal microscope.
doi:10.1371/journal.pone.0027091.g009

have contributed to removal of DlasB mutant bacteria. We are
currently examining in detail the susceptibility of these pulmonary
innate immunity proteins to LasB.
In conclusion, our study demonstrates that DlasB mutant is
unable to degrade mSP-A. This leads to more efficient clearance
by SP-A-mediated opsonization in infected mouse lungs. Therapeutic strategies aiming at inactivating the activity of this
exoprotease may enhance the clearance of P. aeruginosa, and
reduce the morbidity and mortality during lung infections
mediated by this versatile pathogen.

in Luria-Bertani Broth (LB) for 16 hr at 37uC, resuspended in LB
with 20% glycerol and frozen in aliquots at -80uC. Before each
experiment, bacteria were cultured from frozen stocks in LB with or
without antibiotics to stationary phase (OD600nm < 3.0). Bacterial
density was determined spectrophotometrically and was correlated
with numbers of viable bacteria by colony-forming units (cfu) after
plating serial dilutions on agar plates. When required, antibiotics
were used at the following concentrations: for P. aeruginosa,
carbenicillin (300 mg/ml), gentamicin (30 mg/ml), spectinomycin
(100 mg/ml), tetracycline (60 mg/ml); for Escherichia coli DH5a (66),
carbenicillin (100 mg/ml) and tetracyclin (20 mg/ml).

Materials and Methods

Murine macrophage cell line

Chemicals

Murine RAW 264.7 macrophages (ATCC #TIB-71) were
maintained in DMEM supplemented with 10% FBS, and 1%
streptomycin and penicillin, respectively, at 37uC in the presence
of 5% CO2.

All chemicals were purchased from Sigma Chemical Co. (St.
Louis, MO), unless stated otherwise.

Bacterial strains, media and growth conditions
Purification of human SP-A

The parental wild-type P. aeruginosa PAO1 strain was originally
obtained from Dr. Michael Vasil as previously described [22,27,64].
The LasB-deficient mutant PDO240 (DlasB) was derived by gene
replacement by McIver et al [65] in the same PAO1 strain. The
genetically-complemented strain PDO240LasB was derived by
transforming the DlasB mutant with the plasmid pKSM3 carrying
a copy of the wild-type lasB gene [38]. Bacterial strains were grown
PLoS ONE | www.plosone.org

Human SP-A was purified from the lung washings of patients
with alveolar proteinosis as previously described [67]. Pure hSP-A
samples were stored in membrane permeabilization buffer (5 mM
Tris, 150 mM NaCl, pH 7.4) at -20uC. The preparations were
deemed free of EDTA by a modified spectrophotometric assay,
using ß-phenanthrolene–disulfonic acid as the indicator [68].
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Figure 10. Lysozyme-degrading ability is reduced inDlasB mutant bacteria in vitro and in vivo. (A) Chicken lysozyme (5 mg) was incubated
with 16108 PAO1, DlasB or PDO240LasB bacteria for the indicated time intervals. Lysozyme degradation was assessed by western blot analyses using
10 ml of lysozyme/bacterial suspension. (B) Elastase deficient DlasB mutant is attenuated in the degradation of mouse lysozyme during lung infection.
BAL fluids from Fig. 5C were used for western blot analyses. (C) Densitometry quantification of chicken lysozyme degradation in A. (D) Densitometry
analysis of lysozyme degradation by PAO1, DlasB and PDO240lasB in mouse lungs 18 hr post-infection. The amounts of remaining mouse lysozyme in
DlasB were set to the value of 100%. *p,0.05 when compared with the amount of lysozyme in BAL fluids from lungs infected with PAO1 or
PDO240lasB against BAL fluids from DlasB-infected mice.
doi:10.1371/journal.pone.0027091.g010

air. The animals received autoclaved food, water, and bedding.
Mice were handled in accordance with approved protocols through
the Institutional Animal Care and Use Committee at the University
of Illinois at Urbana-Champaign.

Protein assays
Protein concentrations were routinely determined by the
bicinchoninic acid protein assay kit (BCA; Pierce Chemical Co.,
Rockford, IL, USA), using bovine serum albumin (BSA) as a
standard. Protein samples were resolved on 8–16% SDS-PAGE
gel and stained with Coomassie blue or silver nitrate.

Mouse infection

Single intranasal infections of SP-A+/+ and SP-A-/- mice (groups
of 4-8) were performed with 16107 of PAO1, DlasB or
PDO240LasB bacteria as we have previously published
[22,26,27]. After 18 hr, mouse lungs (n = 5) were harvested for
bacterial enumeration, or broncho-alveolar lavaged (BAL) for
proteins used in western blots or membrane permeabilization
analyses (n = 5-8). Virulence attenuation was defined as the log10
difference in CFU of various P. aeruginosa bacteria recovered from
the lung tissues of SP-A+/+ versus SP-A-/- mice.

Animal husbandry
Swiss Black SP-A-/- mice, a gift of J. Whitsett/T. Korfhagen,
were derived from embryonic stem cells after disruption of the
mouse SP-A gene by homologous recombination and were
maintained by breeding with Swiss Black mice [69]. The SP-A
null allele was backrossed into the C3H/HeN genetic background
through nine generations [25]. C3H/HeN control (SP-A+/+) mice
were purchased from Harlan Laboratory (South Easton, MA). All
comparisons made with the SP-A-/- mice were with age- and strainmatched C3H/HeN controls. All animals were housed in positively
ventilated microisolator cages with automatic recirculating water
located in a room with laminar, high efficiency particulate-filtered
PLoS ONE | www.plosone.org

BAL
BAL was performed on P. aeruginosa-infected mice (n = 5) as we
have previously described [22,27]. The trachea was exposed and
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intubated with a 1.7-mm outer diameter polyethylene catheter.
BAL was performed by instilling PBS in 361 ml aliquots per
mouse. In some experiments, the BAL samples were pooled for
membrane permeabilization assays.

In vitro phagocytosis assays
For in vitro phagocytosis experiments, approximately 16106
RAW 264.7 macrophages were plated on 6-well tissue culture
plates overnight. Macrophages were exposed to 107 P. aeruginosa
cells in the presence of intact hSP-A (10–50 mg/ml), or to a
mixture of 16107 P. aeruginosa bacteria and (20 mg/ml) hSP-A that
had been incubating for 1, 6, 12 or 18 hr. After 1 hr of infection,
monolayer cells were washed 3 times with PBS and incubated with
DMEM containing 100 mg/ml gentamicin for 1 hr to kill off
extracellular bacteria [69]. Cells were washed again to remove
gentamicin, and lysed with 0.5% Triton X-100. The intracellular
bacteria were serial diluted for cfu enumeration on agar plates.

Flow cytometry of mouse lung leukocytes
BAL fluids from P. aeruginosa-infected mice (n = 5) were
centrifuged and resuspended in flow cytometry staining buffer.
Cells were pre-incubated with anti-mouse CD16/CD32 (cat#: 140161, eBioscience, San Diego, CA) for 20 minutes on ice prior to
staining to block non-specific Fc-mediated interactions. Mouse
macrophages were labeled with primary antibody anti-mouse F4/
80-PE (cat#: 12-4801-80, eBioscience). Mouse neutrophils were
labeled with anti-mouse Ly-6G-FITC (cat#: 11-5931-81,
eBioscience). Flow cytometric acquisition was performed using a
C6 flow cytometer (Accuri, Ann Arbor, MI) and analyzed with
CFlow Plus version 1.0.

In vivo phagocytosis assays
For in vivo phagocytosis assays, 16107 P. aeruginosa bacteria were
intranasally inoculated into the lungs of SP-A+/+ mice (n = 5).
Infected lungs were BAL at indicated time intervals with PBS to
obtain alveolar leukocytes. BAL samples were centrifuged and
washed three times with PBS. Leukocytes were treated with
DMEM containing 100 mg/ml gentamicin for 1 hr to kill off
extracellular bacteria. The bacteria that were internalized by
phagocytes were enumerated using the gentamicin exclusion
assays.

Membrane permeabilization assays
The effect of SP-A on the cell membrane integrity of P.
aeruginosa and E. coli DH5a was assessed by determining
permeability to a phosphatase substrate, Enzyme-Labeled Fluorescence 97 (ELF-97) (Molecular Probes, Carlsbad, CA), as we
have previously described [22,26,27]. hSP-A (50 mg/ml) or mouse
BAL fluids (50 mg total protein) was incubated with 16108
stationary phase P. aeruginosa or E. coli bacteria/ml in 100 ml of
membrane permeabilization buffer for 15 min at 37uC, and
100 mM ELF97 phosphatase substrate was added. Fluorescence
was measured at excitation and emission wavelengths of 355 and
535 nm, respectively, for 90 - 120 min.

Bacterial aggregation assays
The susceptibility of the wild-type P. aeruginosa PAO1 and DlasB
mutant bacteria to aggregation by SP-A was assessed by
aggregation assay. Briefly, 16107 stationary phase P. aeruginosa
bacteria transformed with pUC19-GFP were incubated with hSPA (20 mg/ml) in 500 ml of DMEM medium supplemented with
2 mM CaCl2. The mixtures were rotated at 37uC for 60 min at
120 rpm. Each mixture (10 ml) was spotted on slides and observed
under LEICA DMI4000 fluorescent microscope. The number of
bacterial clusters was enumerated from 10 independent fields
under 10x magnification, in three independent experiments. For ex
vivo aggregation, mouse lungs of SP-A+/+ mice (n = 5) infected with
16107 wild-type P. aeruginosa PAO1-GFP or PDO240-GFP
(Table 1) were lavaged at 18 hr post infection. Bacterial aggregates
within BAL fluids were observed directly under FLUOVIEW
FV300 confocal microscope.

Exoprotease assays
Exoprotease activities were determined by the SensolyteTM Red
Protease Assay Kit (AnaSpec Inc, San Jose, CA, Cat # 71140)
using cell-free supernatants of stationary phase cultures from P.
aeruginosa PAO1, DlasB or PDO240LasB grown in LB.

In vitro hSP-A and lysozyme degradation assays
P. aeruginosa strains PAO1, DlasB or PDO240LasB bacteria were
cultured in LB overnight to late stationary phase. hSP-A (25 mg) or
chicken lysozyme (5 mg) was added to 16108 P. aeruginosa cells
resuspended in 250 ml of fresh LB supplemented with 2 mM
CaCl2 in the presence or absence of 0.6 mM ZnCl2. At indicated
time intervals, a 10 ml aliquot of each bacterial-SPA mixture or
cell-free supernatants was mixed with loading buffer for SDSPAGE and Western blot analysis.

ELISA assays
Protein levels of chemokines CCL5 and MCP1 in BAL or lung
homogenates were determined by ELISA according to the
manufacturer’s protocols (Invitrogen, Carlsbad, CA).

Statistical analyses

Western blot

Statistical analysis was performed using the Student’s t-test and
one-way analyses of variance (ANOVA). A significant difference
was considered to be p,0.05.

Western blot analyses were performed using standard protocols
[70]. Briefly, protein samples of hSP-A, mouse BAL fluids, P.
aeruginosa bacteria or culture supernatants were resolved by SDSPAGE and electro-blotted onto Immobilon P polyvinylidene
difluoride membranes (Millipore, Bedford, MA). The membranes
were then incubated for 60 min at room temperature in blocking
solution (PBS containing 3% BSA), followed by a 4-hr incubation
with polyclonal antibody against hSP-A and mSP-A (Santa Cruz
Biotecnology Inc, Santa Cruz, CA), a polyclonal antibody against
chicken and mouse lysozymes [57], or with a polyclonal antibody
against LasB [38,39]. The membranes were hybridized with
horseradish peroxidase-conjugated goat anti-mouse IgG secondary
antibody. Immune complexes were visualized using the ECL Western
Blotting Detection System (Amershan Biosciences, Piscataway, NJ)
and Kodak BIOMAX (Kodak, Rochester, NY) X-ray films.
PLoS ONE | www.plosone.org

Supporting Information
Figure S1 SP-A-degrading ability is reduced in DlasB
mutant bacteria in vitro. (A) hSP-A (25 mg) was incubated
with 16108 PAO1, DlasB or PDO240LasB bacteria in LB
supplemented with 0.6 mM ZnCl2 for the indicated time intervals.
hSP-A degradation was assessed by western blot analyses using
10 ml of SP-A/bacterial suspension. Image from one of the three
independent experiments is shown. (B) hSP-A degradation P.
aeruginosa strains in the absence of ZnCl2. Immunoblots were
probed with anti-SP-A antibody.
(TIF)
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